Takeda announced the European Medicines Agency’s, or EMA, Committee for Medicinal Products for Human Use, or CHMP, has recommended the approval of Hyqvia in patients with chronic inflammatory demyelinating polyneuropathy, or CIDP, as maintenance therapy after stabilization with intravenous immunoglobulin therapy, or IVIG. The European Commission will consider the CHMP positive opinion when determining the potential marketing authorization for HYQVIA for CIDP throughout the European Union.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on TAK:
- Takeda says FDA approves ADZYNMA
- FDA approves Takeda’s Adzynma for rare inherited blood clotting disorder
- Takeda gets FDA approval of Fruzaqla for previously treated colorectal cancer
- Stifel downgrades Ventyx Biosciences after ‘disappointing’ VTX958 data
- Takeda announces European Commission approves ADCETRIS in Hodgkin lymphoma
